Biogen's Diranersen Drug Shows Promise in Slowing Alzheimer's Progression
724FinanceDr. Yaman Ege
Key Highlights
Biogen'in diranersen adlı deneysel Alzheimer ilacının ilk klinik test sonuçları ortaya çıktı. Çoklu skleroz hastalarına uygulanan ilaç, hastaların bil
Initial clinical trial results for Biogen's experimental Alzheimer's drug, diranersen, have shown promising results. When administered to multiple sclerosis patients, the drug slowed cognitive decline by 30%. This suggests potential for early-stage Alzheimer's prevention. The experimental medication reduced amyloid plaque formation, allowing brain cells to function more efficiently. Biogen plans to advance diranersen to broader clinical trials. The development could mark a significant breakthrough in Alzheimer's treatment.
Related News & Analysis
View All →
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Inertia Enterprises Cuts Fusion Fuel Loading to Hours, Shaking the Energy Market
Latest Market News
All News →![[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş.
Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu](/_next/image?url=%2Fuploads%2Fkap-default.png&w=3840&q=75)
[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Moderna’s Personalized mRNA Gamble: Oncology Revolution or Market Bubble?
[GSRAY] GALATASARAY SPORTİF SINAİ VE TİCARİ YATIRIMLAR A.Ş. Transfer Görüşmelerinin Sonuçlanması veya Sona Ermesi - Profesyonel Futbolcu Aleksei Batrakov Transferi Hakkında
Norway’s July Oil Production Slump Sends Shockwaves Through European Energy Markets
